Catalyst Event
Peptron Inc (087010) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
6/2/2026, 12:00:00 AM
Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.
Korean Translation
일라이 릴리가 2026년 6월 1일 경쟁사인 카무루스와의 협력 확대 옵션을 행사함에 따라 펩트론 스마트데포 플랫폼과의 경쟁 심화로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
LigaChem Biosciences Inc (141080) · Other
Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.
6/4/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The company's natural new drug for gastritis, 'Zitec', is scheduled to receive conditional reimbursement approval from the Health Insurance Review and Assessment Service's (HIRA) drug evaluation committee on June 4, 2026, provided the company accepts a price below the evaluated amount. Estimated price impact >=5% as this is a critical step for market entry scheduled.
6/4/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.
6/4/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a partnership with Chime Biologics for the development and commercialization of a biosimilar for the immunology drug 'Dupixent', a blockbuster drug with estimated global sales of KRW 27 trillion.
6/2/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.
6/1/2026, 12:00:00 AM
Voronoi Inc (310210) · Other
Voronoi presented positive clinical trial data for VRN11 at ASCO 2026 on June 1, 2026. High importance is estimated due to strong anti-tumor response in brain metastases, a major unmet need, scheduled.
6/1/2026, 12:00:00 AM